Melanoma trial failure deals heavy blow to immunotherapy hopes
Merck slides and Incyte loses $4bn market value as ‘combination’ cancer study flops
Source: FT.com - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Merck | Pharmaceuticals | Skin Cancer | Study